Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.
Publication
, Conference
Shore, ND; Moul, JW; Crawford, E; Olesen, T; Persson, B
Published in: Journal of Clinical Oncology
May 20, 2010
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
4673 / 4673
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shore, N. D., Moul, J. W., Crawford, E., Olesen, T., & Persson, B. (2010). Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. In Journal of Clinical Oncology (Vol. 28, pp. 4673–4673). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.4673
Shore, N. D., J. W. Moul, E. Crawford, T. Olesen, and B. Persson. “Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.” In Journal of Clinical Oncology, 28:4673–4673. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.4673.
Shore ND, Moul JW, Crawford E, Olesen T, Persson B. Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 4673–4673.
Shore, N. D., et al. “Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 4673–4673. Crossref, doi:10.1200/jco.2010.28.15_suppl.4673.
Shore ND, Moul JW, Crawford E, Olesen T, Persson B. Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 4673–4673.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15_suppl
Start / End Page
4673 / 4673
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences